StoxLupin vs Max Healthcare Institute: share price & financials comparison
NSE: LUPIN vs MAXHEALTH · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Lupin vs Max Healthcare Institute at a glance
Lupin (LUPIN) has a market capitalisation of ₹90,916 Cr, against ₹90,907 Cr for Max Healthcare Institute (MAXHEALTH). Over the past year Lupin has returned +1.6%, compared with -21.5% for Max Healthcare Institute. On valuation, Lupin trades at a lower P/E of 17.5 versus 65.8. Lupin earns a higher return on equity (21.6% vs 12.2%). Lupin comes out ahead on size, valuation, profitability and financial health. Max Healthcare Institute comes out ahead on growth, momentum and technicals. Across the scored metrics below, Lupin leads on 10 and Max Healthcare Institute on 7. On StoxGud's 10-point checklist, Lupin scores 7/10 and Max Healthcare Institute scores 3/10.
| Metric | Lupin | Max Healthcare Institute |
|---|---|---|
| Size | ||
| Market cap | ₹90,916 Cr | ₹90,907 Cr |
| Revenue (latest FY) | ₹27,958 Cr | ₹8,373 Cr |
| Net profit (latest FY) | ₹5,333 Cr | ₹1,442 Cr |
| Valuation | ||
| P/E | 17.5 | 65.8 |
| P/B | 3.78 | 8.02 |
| Dividend yield | 0.60% | 0.16% |
| Profitability | ||
| Return on equity | 21.6% | 12.2% |
| Net profit margin | 16.9% | 15.1% |
| Operating margin | 30.1% | 26.8% |
| Growth | ||
| Revenue growth (YoY) | +11.1% | +20.3% |
| Net profit growth (YoY) | -21.8% | -15.5% |
| Revenue CAGR (multi-year) | +13.0% | +27.3% |
| Financial health | ||
| Debt to equity | 0.23 | 0.33 |
| Momentum | ||
| 1-month return | -1.2% | +2.9% |
| 1-year return | +1.6% | -21.5% |
| 3-year CAGR | +18.3% | +16.3% |
| 5-year CAGR | +16.4% | +22.5% |
| 10-year CAGR | +2.7% | — |
| Distance from 52W high | -20.9% | -20.9% |
| Technicals | ||
| RSI (14) | 55 | 79 |
| Price vs 200-day avg | -11.2% | -7.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Lupin | Max Healthcare Institute |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 7/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Lupin or Max Healthcare Institute?
Lupin has a market cap of ₹90,916 Cr and Max Healthcare Institute has a market cap of ₹90,907 Cr as of 06 Nov 2026.
Which has a lower P/E, Lupin or Max Healthcare Institute?
Lupin has the lower P/E: Lupin trades at 17.5 and Max Healthcare Institute at 65.8.
Which gave better returns in the last year, Lupin or Max Healthcare Institute?
Lupin did better: Lupin returned +1.6% and Max Healthcare Institute returned -21.5% over one year.
Is Lupin or Max Healthcare Institute a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Lupin scores 7/10 and Max Healthcare Institute scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.